Ipamorelin
IPA · Ipam
The gentlest growth hormone peptide. Strong GH release without the hunger or cortisol spike.
Educational content only. Not medical advice. This compound may be regulated in your jurisdiction. Consult a healthcare professional.
01 What is Ipamorelin?
Ipamorelin is widely considered the cleanest growth hormone releasing peptide (GHRP) available. Unlike older GHRPs like GHRP-6 (which makes you want to eat everything in sight) or GHRP-2 (which spikes cortisol), Ipamorelin selectively stimulates GH release without significantly affecting appetite, cortisol, or prolactin. That selectivity is why it has become the go-to peptide for people who want GH benefits without dealing with side effects. In the biohacking community, Ipamorelin is often the first peptide people try — and for good reason. The side effect profile is mild, the GH release is dose-dependent and predictable, and it pairs beautifully with CJC-1295 (Mod GRF) for a synergistic effect that mimics the body's natural GH pulsatile release pattern. Think of it as pressing the GH release button without setting off all the other alarms in the building. Your pituitary releases GH, you get the recovery and sleep benefits, and the rest of your endocrine system barely notices.
02 How Does It Work?
Ipamorelin is a pentapeptide that acts as a selective agonist of the ghrelin/GHS receptor (GHSR) on pituitary somatotrophs. It triggers GH release by mimicking ghrelin's action at the pituitary level, but with much greater selectivity — it does not significantly activate ghrelin's appetite-stimulating or cortisol-releasing pathways. The selectivity comes from its unique binding profile. While it hits the GHSR receptor like other GHRPs, it does not trigger the downstream cascades that lead to increased ACTH/cortisol or the intense hunger that ghrelin itself causes. The result is a clean, dose-dependent GH pulse.
03 What Does The Research Say?
Moderate evidence. Some human data, mostly animal studies.
Multiple clinical studies exist. A Phase II trial in post-surgical patients showed Ipamorelin was well-tolerated and effectively stimulated GH release without affecting cortisol, prolactin, FSH, LH, or TSH — confirming its selectivity. Studies in both humans and animals consistently show dose-dependent GH release. Novo Nordisk developed it through Phase II trials for various indications including post-operative ileus (gut recovery after surgery). While it never reached market approval, the clinical data established its safety and efficacy profile. Research also shows it does not desensitize GH release even with repeated dosing — unlike some other GHRPs.
04 Reported Dosages
Research literature dosages only. NOT medical recommendations. Always consult a healthcare professional.
Clinical trials used 1-30 mcg/kg IV or subcutaneous. Community protocols typically use 100-300 mcg subcutaneously, 1-3 times daily. Often paired with Mod GRF 1-29 at equal doses for synergistic effect. Best taken on an empty stomach, commonly before bed. These are research dosages, not medical recommendations.
05 Side Effects & Risks
Generally very well-tolerated. Mild head rush or flushing immediately post-injection, occasional headache, rare injection site irritation. No significant appetite increase (unlike GHRP-6). No meaningful cortisol or prolactin elevation at standard doses.
06 Legal Status
Not approved for human use. Available as research chemical.
Not FDA-approved. Research chemical. Not scheduled.
Not approved. Research chemical.
Not approved. TGA Schedule 4. Banned by WADA.
Goal Guides for Ipamorelin
Explore how Ipamorelin may support specific health goals: